## fiSCal 2013 TOpiCS 

## N Continuous Launch of New Products 

2013 

May P  Launch in Japan of Micamlo Combination Tablets BP for hypertension containing high-dose ingredient 

Jun. P  Launch in Japan of Acofide for functional dyspepsia treatment 

Jul. P  Launch in U.K. of XTANDI for prostate cancer treatment 

Aug. P  Launch in the U.S. of ASTAGRAF XL (extended-release capsules), a new formulation of immunosuppressant Prograf 

Sep. P  Launch in Europe of VESOMNI, a combination tablet of solifenacin and tamsulosin (generic name) for treatment of voiding symptoms in protostatic hyperplasia 

2014 

P  Launch in Japan of Bisono Tape, a transdermal anti-hypertensive treatment 

Jan. P  Launch in Japan of Irribow OD Tablets for diarrhea-predominant irritable bowel syndrome 

## N R&D Alliances with Other Companies 

2013 

P  Marketing approval received in Japan for Suglat for treatment of type 2 diabetes 

$_{R}$ Launched in April 2014 

Mar. P  Marketing approval received in Japan for XTANDI for prostate cancer treatment 

$_{R}$ Launched in May 2014 

May P  Agreement on strategic alliance in Japan signed with Amgen Inc. 

—Co-development and co-commercialization of five Amgen pipeline products and establishment of Amgen Astellas BioPharma K.K. 

Jun. P  Collaboration agreement signed with Cytokinetics, Inc. in the field of skeletal muscle disease 

Oct. P  Collaboration agreement signed with Mitokyne, Inc. in the area of mitochondria-related diseases 

P  Established Astellas Innovation Management to identify and obtain external innovation opportunities 

Dec. P  Astellas and Immuno-Biological Laboratories Co., Ltd. concluded a co-research agreement regarding 

2014 

pharmaceutical applications of recombinant human proteins made using transgenic silkworms 

Jan. P  Formed a strategic alliance with ClearPath Development Company to build vaccine portfolio 

—Invested in respiratory syncytial virus vaccine development 

Mar. P  Entered collaboration agreement with Daiichi Sankyo Company, Limited regarding sharing of compound libraries 

